46,208 Shares in LeMaitre Vascular, Inc. (NASDAQ:LMAT) Acquired by Dividend Assets Capital LLC

Dividend Assets Capital LLC purchased a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 46,208 shares of the medical instruments supplier's stock, valued at approximately $3,877,000. Dividend Assets Capital LLC owned approximately 0.20% of LeMaitre Vascular at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Smartleaf Asset Management LLC increased its stake in shares of LeMaitre Vascular by 234.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 293 shares in the last quarter. CBIZ Investment Advisory Services LLC increased its stake in shares of LeMaitre Vascular by 38.5% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 117 shares in the last quarter. NBC Securities Inc. bought a new position in shares of LeMaitre Vascular in the 1st quarter worth about $36,000. Huntington National Bank increased its stake in shares of LeMaitre Vascular by 64.9% in the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock worth $107,000 after acquiring an additional 455 shares in the last quarter. Finally, Empowered Funds LLC bought a new position in shares of LeMaitre Vascular in the 4th quarter worth about $150,000. 84.64% of the stock is currently owned by institutional investors.

LeMaitre Vascular Stock Down 0.3%

Shares of NASDAQ LMAT traded down $0.24 during trading on Friday, reaching $81.13. 229,261 shares of the company traded hands, compared to its average volume of 168,943. The firm has a 50 day simple moving average of $83.79 and a 200-day simple moving average of $90.46. The stock has a market capitalization of $1.83 billion, a PE ratio of 44.33, a P/E/G ratio of 2.22 and a beta of 0.83. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The company had revenue of $59.87 million for the quarter, compared to analysts' expectations of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business's revenue was up 12.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.44 EPS. As a group, research analysts predict that LeMaitre Vascular, Inc. will post 1.94 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, May 29th. Stockholders of record on Thursday, May 15th were issued a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.99%. The ex-dividend date was Thursday, May 15th. LeMaitre Vascular's payout ratio is presently 40.40%.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Lake Street Capital increased their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective on the stock. Five analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, LeMaitre Vascular has an average rating of "Hold" and a consensus target price of $97.83.

Insider Activity

In related news, CEO George W. Lemaitre sold 18,733 shares of the firm's stock in a transaction that occurred on Friday, May 16th. The shares were sold at an average price of $84.77, for a total value of $1,587,996.41. Following the transaction, the chief executive officer now owns 1,873,651 shares of the company's stock, valued at approximately $158,829,395.27. This trade represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold a total of 100,000 shares of company stock valued at $8,556,857 in the last 90 days. 9.50% of the stock is currently owned by insiders.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.